Načítá se...
Qiliqiangxin improves cardiac function and attenuates cardiac remodelling in doxorubicin-induced heart failure rats
CONTEXT: Therapeutic doxorubicin administration is restricted as this anticancer drug may be cardiotoxic. The traditional Chinese medicine qiliqiangxin has been approved for clinical treatment of chronic heart failure. OBJECTIVE: To explore the protective effects and molecular mechanisms of qiliqian...
Uloženo v:
| Vydáno v: | Pharm Biol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7301709/ https://ncbi.nlm.nih.gov/pubmed/32429724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13880209.2020.1761403 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|